Inter- and intrapatient variability in oral topotecan pharmacokinetics: Implications for body-surface area dosage regimens

Clinical Cancer Research

Volumn 6, Issue 7, 2000, Pages 2685-2689

  Loos, Walter J ^a   Gelderblom, Hans ^a   Sparreboom, Alex ^a   Verweij, Jaap ^a   De Jonge, Maja J A ^a  

^a ERASMUS MC CANCER INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; TOPOTECAN;

AREA UNDER THE CURVE; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL TRIAL; DOSE CALCULATION; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG CLEARANCE; HUMAN; MAJOR CLINICAL STUDY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; BODY SURFACE AREA; CISPLATIN; CLINICAL TRIALS, PHASE I; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; HUMANS; NEOPLASMS; PATIENT SELECTION; RETROSPECTIVE STUDIES; TOPOTECAN;

EID: 0033927215     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Gurney, H. Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative. J. Clin. Oncol., 14: 2590-2611, 1996.
2. Bruno, R., Vivier, N., Vergniol, J. C., De Phillips, S. L., Montay, G., and Sheiner, L. B. A population pharmacokinetic model for docetaxel (Taxotere): model building and validation. J. Pharmacokinet. Biopharm., 24: 153-172, 1996.
3. Gerrits, C. J. H., Schellens, J. H. M., Burris, H., Eckardt, J. R., Planting, A. S. T., Van der Burg, M. E. L., Rodriguez, G. I., Loos, W. J., Van Beurden, V., Hudson, I., Von Hoff, D. D., and Verweij, J. A comparison of clinical pharmacodynamics of different administration schedules of oral topotecan. Clin. Cancer Res., 5: 69-75, 1999.
4. Herben, V. M. M., Ten Bokkel Huinink, W. W., and Beijnen, J. H. Clinical pharmacokinetics of topotecan. Clin. Pharmacokinet., 31: 85-102, 1996.
5. Herben, V. M. M., Ten Bokkel Huinink, W. W., Schellens, J. H. M., and Beijnen, J. H. Clinical pharmacokinetics of camptothecin topoisomerase I inhibitors. Pharm. World. Sci., 20: 161-172, 1998.
6. Zamboni, W. C., Stewart C. F., Thompson, J., Santana, V. M., Cheshire, P. J., Richmond, L. B., Luo, X., Poquette, C., Houghton, J. A., and Houghton, P. J. Relationship between topotecan systemic exposure and tumor response in human neuroblastoma xenografts. J. Natl. Cancer Inst., 90: 505-511, 1998.
7. Schellens, J. H. M., Creemers, G. J., Beijnen, J. H., Rosing, H., De Boer-Dennert, M., McDonald, M., Davies, B., and Verweij, J. Bioavailability and pharmacokinetics of oral topotecan: a new topoisomerase I inhibitor. Br. J. Cancer, 73: 1268-1271, 1996.
8. Herben, V. M. M., Rosing, H., Ten Bokkel Huinink, W. W., Van Zoomeren, D. M., Batchelor, D., Doyle, E., Beusenberg, F. B., Beijnen, J. H., and Schellens, J. H. M. Oral topotecan: bioavailability and effect of food co-administration. Br. J. Cancer, 80: 1380-1386, 1999.
9. Kuhn, J., Rizzo, J., Eckardt, J., Fields, S., Cobb, P., Rodriguez, G., Rinadi, D., Drengler, R., Smith, L., Peacock, N., Thurman, A., DeLaCruz, P., Hodges, S., Von Hoff, D. D., and Burris, H. Phase I bioavailability study of oral topotecan. Proc. Am. Soc. Clin. Oncol. Annu. Meet., 14: 474, 1995.
10. Gerrits, C. J. H., Burris, H., Schellens, J. H. M., Planting, A. S. T., Van der Burg, M. E. L., Rodriguez, G. I., Van Beurden, V., Loos, W. J., Hudson, I., Fields, S., Verweij, J., and Von Hoff, D. D. Five days of oral topotecan (Hycamtin), a phase I and pharmacological study in adult patients with solid tumors. Eur. J. Cancer, 34: 1030-1035, 1998.
11. Creemers, G. J., Gerrits, C. J. H., Eckardt, J. R., Schellens, J. H. M., Burris, H. A., Planting, A. S. T., Rodriguez, G. I., Loos, W. J., Hudson, I., Broom, C., Verweij, J., and Von Hoff, D. D. Phase I and pharmacologic study of oral topotecan administered twice daily for 21 days to adult patients with solid tumors. J. Clin. Oncol., 15: 1087-1093, 1997.
12. Gerrits, C. J. H., Burris, H., Schellens, J. H. M., Eckardt, J. R., Planting, A. S. T., Van der Burg, M. E. L., Rodriguez, G. I., Loos, W. J., Van Beurden, V., Hudson, I., Fields, S., Von Hoff, D. D., and Verweij, J. Oral topotecan given once or twice daily for ten days: a phase I and pharmacology study in adult patients with solid tumors. Clin. Cancer Res., 4: 1153-1158, 1998.
13. Ratain, M. J. Body-surface area as a basis for dosing of anticancer agents: science, myth, or habit? (Editorial). J. Clin. Oncol., 16: 2297-2298, 1998.
14. de Jonge, M. J. A., Loos, W. J., Gelderblom, H., Planting, A. S. T., van der Burg, M. E. L., Sparreboom, A., Brouwer, E., van Beurden, V., Mantel, M. A., Doyle, E., Hearn, S., Ross, G., and Verweij. J. Phase I pharmacologic study of oral topotecan and intravenous cisplatin: sequence dependent hematologic side-effects. J. Clin. Oncol., 18: 2104-2115, 2000.
15. Loos, W. J., Stoter, G., Verweij, J., and Schellens, J. H. M. Sensitive high-performance liquid Chromatographic fluorescence assay for the quantitation of topotecan (SKF 104864-A) and its lactone ring-opened product (hydroxy-acid) in human plasma and urine. J. Chromatogr. B, 678: 309-315, 1996.
16. O'Reilly, S., Rowinsky, E. K., Slichenmyer, W., Donehower, R. C., Forastiere, A. A., Ettinger, D. S., Chen, T. L., Sartorius, S., and Grochow, L. B. Phase I and pharmacologic study of topotecan in patients with impaired renal function. J. Clin. Oncol., 12: 3062-3073, 1996.
17. Jonker, J. W., Smit J. W., Wagenaar, E., Maliepaard, M., Schellens, J. H. M., and Schinkel, A. H. P-glycoprotein reduces the oral availability of topotecan in mice. Proc. Am. Assoc. Cancer Res. Annu. Meet., 91: 814, 2000.